Notes to the company financial statements 1.
Accounting policies The accounting policies adopted in the preparation of these Company financial statements are the same as those set out in note 2 to the Group financial statements with the addition of the following: Investments Investments in subsidiaries are stated at cost less provision for impairment.
Accounting for transactions under common control Where the Company acquires or disposes of shares in another Group company either in a share for share exchange or as an acquisition or disposal of part of the business, the cost or proceeds are determined by reference to the fair value of the consideration received i. e. the fair value of the company in which shares have been received at the date of transfer.
If the Company receives shares following the sale of its subsidiary or part of its business, any gain or loss is credited or charged to the income statement.
Where the Company issues shares following the acquisition of a subsidiary or part of another business, any gain or loss is credited or charged to reserves.
Share-based payments The Company has elected to apply IFRS2 to all share-based awards and options granted post 7 November 2002 that had not vested by 1 January 2005.
The carrying amount of an investment in a subsidiary is increased to the extent that share-based payments relate to employees of that subsidiary.
Share-based payment expenses relating to employees of the Company are expensed within the income statement.
These policies have been applied consistently to the periods presented.
The functional currency of the Company is sterling and all values are rounded to the nearest 0.1m except where otherwise indicated.
Loss for the year As permitted by section 408 of the Companies Act 2006, the Company has elected not to present its own income statement for the year.
The loss after tax of the Company amounted to 4.6m 2013: 3.3m.
The analysis of the auditors remuneration is as follows: Year ended Year ended 31 March 31 March 2014 2013 000 000 The auditing of accounts of the Company 94 93 Audit related assurance services 54 50 3.
Staff costs The employees are based in the United Kingdom.
Disclosures of individual Directors remuneration and associated costs required by the Companies Act 2006 and specified by the Financial Services Authority are on pages 51 to 68 within the directors remuneration report and form part of these audited accounts.
The employees of the Company are members of the Group pension schemes as detailed in note 22 of the Group financial statements.
The Company receives a charge based upon the employer contribution to the Groups defined benefit pension scheme.
No additional contributions are paid by the Company.
Investment in subsidiary undertakings m Cost At 1 April 2012 365.9 Share based payments 3.4 At 1 April 2013 369.3 Transfers of investments to subsidiary companies 244.1 Share based payments 4.1 At 31 March 2014 617.5 During the year BTG plc, in conjunction with the broader Group undertook the transfer of several investments within the Group structure.
There was no share-for-share consideration offered as part of these non-cash settled transactions.
A list of the Companys principal subsidiary undertakings is shown in note 32 to the Group financial statements.
BTG plc Annual Report and Accounts 2014 119 Financials Notes to the company financial statements 5.
Trade and other receivables 31 March 31 March 2014 2013 m m Due within one year Prepayments 0.8 0.4 Amounts owed by subsidiary undertakings 71.2 215.3 72.0 215.7 6.
Capital and reserves Share Share Merger Retained capital premium reserve earnings Total m m m m m Company At 1 April 2012 32.7 188.3 317.8 41.1 579.9 Loss for financial year 3.3 3.3 Total recognised loss for the year 3.3 3.3 Movement in shares held by Trust 0.6 0.6 Other share capital issued 0.1 0.3 0.4 Share-based payments 4.7 4.7 At 1 April 2013 32.8 188.6 317.8 43.1 582.3 Loss for financial year 4.6 4.6 Total recognised loss for the year 4.6 4.6 Movement in shares held by Trust 0.4 0.4 Other share capital issued 3.3 100.1 103.4 Share-based payments 5.3 5.3 At 31 March 2014 36.1 288.7 317.8 44.2 686.8 The merger reserve is used where more than 90% of the shares in a subsidiary are acquired and the consideration includes the issue of new shares by the Company, thereby attracting merger relief under s612 and s613 of the Companies Act 2006.
The balance on the merger reserve has arisen through: 1.
The acquisition of Protherics PLC on 4 December 2008 and includes directly attributable costs of issuing the shares of 0.4m.
The acquisition of Biocompatibles International plc on 27 January 2011 and includes directly attributable costs of issuing of shares of 1.1m.
Details of Company share capital are disclosed in note 19 to the Group financial statements.
Details of share options granted by the Company are set out in note 23 to the Group financial statements.
Details of shares in the Company held by subsidiaries are shown in note 24 to the Group financial statements.
In May 2013, BTG completed a share placing for a total of 32,208,030 new ordinary shares at a price of 330p per placing share, raising proceeds of 106.3m, being 103.1m net of expenses.
Trade and other payables 31 March 31 March 2014 2013 m m Amounts falling due within one year Accruals and deferred income 2.7 2.7 Amounts falling due after more than one year Other The directors consider the fair value to be equal to the book value.
Financial assets and liabilities Total Designated Amortised carrying Fair at fair value cost value value m m m m 31 March 2013 Cash and cash equivalents Trade and other receivables 215.7 215.7 215.7 Trade and other payables 2.7 2.7 2.7 31 March 2014 Cash and cash equivalents Trade and other receivables 72.0 72.0 72.0 Trade and other payables 2.7 2.7 2.7 Credit risk The Companys credit risk is the risk that one of its subsidiaries is unable to repay intercompany amounts owing.
The recoverability of the Companys intercompany receivable is considered at each balance sheet date.
Liquidity risk Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due.
The Company does not hold significant cash balances as Group cash is managed centrally within its subsidiaries.
Accordingly the Company is funded by its subsidiaries as its liabilities fall due.
In April 2013, the Group signed a 60m multi-currency revolving credit facility providing access to funds for a period of three years to April 2016.
This has not been utilised in the period.
Market risk Market risk is the risk that changes in market prices, such as foreign exchange rates, interest rates and equity prices will affect the Groups income or the value of its holdings in financial instruments.
As the holding company of the Group, the Company does not have significant exposure to movements in market prices and accordingly no additional disclosure is provided.
There are no foreign currency balances within the Companys statement of financial position.
Capital Management Details of the Companys objectives with respect to managing capital are disclosed in note 26 to the Group financial statements.
Guarantees and contingent liabilities The Company has entered into an agreement to guarantee payments under the lease of its US subsidiary undertaking.
The Company has provided a Guarantee to certain subsidiary undertakings in respect of the BTG Pension Fund up to a maximum amount equal to the lowest non-negative amount which, when added to the assets of the Fund, would result in the Fund being at least 105% funded on the date on which any liability arose, calculated on the basis set out in section 179 of the Pensions Act 2004, were a valuation to be conducted as at that date.
Related party transactions The Company has a related-party relationship with its subsidiary undertakings and its Directors.
In relation to the related party relationship identified on page 44 concerning Giles Kerr, payments made by BTG to Oxford University and Isis Innovations Ltd under the relevant licence agreements were nil for the year ended 31 March 2014 1.5m during the year ended 31 March 2013.
There are no amounts still outstanding and payable by BTG under these agreements as at 31 March 2014 2013: nil.
Key management personnel are considered to be the Directors and their remuneration is disclosed within the directors remuneration report on pages 51 to 68.
BTG plc Annual Report and Accounts 2014 121 Financials Five year financial record for the year ended 31 March 2014 Consolidated Income statement 1 3 3 2 2014 2013 2012 2011 2010 m m m m m Revenue 290.5 233.7 197.0 111.4 98.5 Cost of sales 95.0 67.2 56.3 34.1 32.8 Gross profit 195.5 166.5 140.7 77.3 65.7 Selling, general and administrative expenses 84.0 58.0 48.9 33.7 25.3 Contribution 111.5 108.5 91.8 43.6 40.4 Amortisation and impairment of acquired intangible assets 23.3 43.4 30.7 10.0 9.1 Amortisation of repurchase of contractual rights 9.6 Foreign exchange gains losses 5.0 3.1 2.6 2.0 4.0 Research and development 47.2 41.2 39.7 32.1 26.7 Profit on disposal of assets and investments 1.1 0.4 0.2 1.5 1.1 Amounts written off property, plant and equipment 1.8 3.0 Amounts written off associates and investments 0.2 1.4 Acquisition and reorganisation costs 9.8 0.1 1.1 3.8 0.7 Share of results of associates 0.3 Operating profit loss 27.3 25.7 19.9 13.8 2.1 Net financial expense income 6.0 1.6 3.1 3.0 7.0 Profit loss before tax 33.3 24.1 23.0 10.8 9.1 Tax 9.0 7.7 8.4 20.0 2.2 Profit loss after tax for the year 24.3 16.4 14.6 9.2 11.3 Earnings loss per share Basic 6.8p 5.0p 4.5p 3.4p 4.4p Diluted 6.7p 5.0p 4.4p 3.4p 4.4p 1 The r esults for the year ended 31 March 2014 include the results of EKOS Corporation and the Targeted Therapies Division of Nordion Inc. from the date of acquisition, being 5 July 2013 and 13 July 2013 respectively.
2 The r esults for the year ended 31 March 2011 include the results of Biocompatibles International plc from the date of acquisition, being 27 January 2011.
3 Onl y financial years 2014 and 2013 have been restated for IAS19 revised.
See accounting policies in note 1 and retirement benefit schemes in note 22 for further details.
2 The statement of financial position for 31 March 2011 includes the assets and liabilities acquired from Biocompatibles International plc during the year 3 Onl y Financial Years 2014 and 2013 have been restated for IAS19 revised.
Consolidated cash flow statement 1 3 3 1 2014 2013 2012 2011 2010 m m m m m Net cash from used in operating activities 48.5 55.5 47.2 12.0 5.8 Net cash from used in investing activities 269.4 4.5 3.9 5.5 2.6 Net cash from used in financing activities 102.7 0.2 0.2 0.6 1.4 Increase decrease in cash and cash equivalents 118.2 51.2 43.1 18.1 4.6 Effect of exchange rate fluctuations on cash held 2.3 0.6 0.1 0.8 0.2 Cash and cash equivalents at start of year 158.7 106.9 63.7 82.6 78.2 Cash and cash equivalents at end of year 38.2 158.7 106.9 63.7 82.6 1 The r esults for the year ended 31 March 2014 include the results of EKOS Corporation and the Targeted Therapies Division of Nordion Inc. from the date of acquisition, being 5 July 2013 and 13 July 2013 respectively.
2 The results for the year ended 31 March 2011 include the results of Biocompatibles International plc from the date of acquisition, being 27 January 2011 3 Onl y financial years 2014 and 2013 have been restated for IAS19 revised.
BTG plc Annual Report and Accounts 2014 123 Financials
